BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 11035936)

  • 1. MYCN-related suppression of functional CD44 expression enhances tumorigenic properties of human neuroblastoma cells.
    Gross N; Balmas Bourloud K; Brognara CB
    Exp Cell Res; 2000 Nov; 260(2):396-403. PubMed ID: 11035936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of functional CD44 hyaluronan receptor on human NMYC-amplified neuroblastoma cells.
    Gross N; Balmas K; Brognara CB
    Cancer Res; 1997 Apr; 57(7):1387-93. PubMed ID: 9102228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD44H expression by human neuroblastoma cells: relation to MYCN amplification and lineage differentiation.
    Gross N; Beretta C; Peruisseau G; Jackson D; Simmons D; Beck D
    Cancer Res; 1994 Aug; 54(15):4238-42. PubMed ID: 7518353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of CD44H carbohydrate structure in neuroblastoma adhesive properties.
    Gross N; Balmas K; Beretta Brognara C
    Med Pediatr Oncol; 2001 Jan; 36(1):139-41. PubMed ID: 11464867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid.
    Ahrens T; Sleeman JP; Schempp CM; Howells N; Hofmann M; Ponta H; Herrlich P; Simon JC
    Oncogene; 2001 Jun; 20(26):3399-408. PubMed ID: 11423990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell lineage and differentiation state are primary determinants of MYCN gene expression and malignant potential in human neuroblastoma cells.
    Spengler BA; Lazarova DL; Ross RA; Biedler JL
    Oncol Res; 1997; 9(9):467-76. PubMed ID: 9495452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Increased expression of the MYCN oncogene in human neuroblastoma cells and possible, new therapeutic approaches].
    Schweigerer L; Fotsis T
    Klin Padiatr; 1991; 203(4):319-22. PubMed ID: 1942938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity.
    Schweigerer L; Breit S; Wenzel A; Tsunamoto K; Ludwig R; Schwab M
    Cancer Res; 1990 Jul; 50(14):4411-6. PubMed ID: 2364393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
    Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
    Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional interaction of Yaf2 with the central region of MycN.
    Bannasch D; Mädge B; Schwab M
    Oncogene; 2001 Sep; 20(41):5913-9. PubMed ID: 11593398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro effects of MYCN sense and antisense expression in MYCN-amplified human neuroblastoma cells.
    Kavallaris M; Gardaneh M; Cheung B; Camacho ML; Hocker JE; Norris MD; Haber M; Marshall GM
    Anticancer Res; 1998; 18(3A):1793-7. PubMed ID: 9673406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD44 hyaluronate binding influences growth kinetics and tumorigenicity of human colon carcinomas.
    Takahashi K; Stamenkovic I; Cutler M; Saya H; Tanabe KK
    Oncogene; 1995 Dec; 11(11):2223-32. PubMed ID: 8570172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYCN downregulates integrin alpha1 to promote invasion of human neuroblastoma cells.
    Tanaka N; Fukuzawa M
    Int J Oncol; 2008 Oct; 33(4):815-21. PubMed ID: 18813796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nmi protein interacts with regions that differ between MycN and Myc and is localized in the cytoplasm of neuroblastoma cells in contrast to nuclear MycN.
    Bannasch D; Weis I; Schwab M
    Oncogene; 1999 Nov; 18(48):6810-7. PubMed ID: 10597290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma.
    Shohet JM; Hicks MJ; Plon SE; Burlingame SM; Stuart S; Chen SY; Brenner MK; Nuchtern JG
    Cancer Res; 2002 Feb; 62(4):1123-8. PubMed ID: 11861392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel human neuronal leucine-rich repeat (hNLRR) family genes and inverse association of expression of Nbla10449/hNLRR-1 and Nbla10677/hNLRR-3 with the prognosis of primary neuroblastomas.
    Hamano S; Ohira M; Isogai E; Nakada K; Nakagawara A
    Int J Oncol; 2004 Jun; 24(6):1457-66. PubMed ID: 15138588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Over-expression of transfected N-myc oncogene in human SKNSH neuroblastoma cells down-regulates expression of beta 1 integrin subunit.
    Judware R; Culp LA
    Oncogene; 1995 Dec; 11(12):2599-607. PubMed ID: 8545117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells.
    Burg MA; Grako KA; Stallcup WB
    J Cell Physiol; 1998 Nov; 177(2):299-312. PubMed ID: 9766527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYCN expression in human rhabdomyosarcoma cell lines and tumour samples.
    Toffolatti L; Frascella E; Ninfo V; Gambini C; Forni M; Carli M; Rosolen A
    J Pathol; 2002 Apr; 196(4):450-8. PubMed ID: 11920742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of one HuD allele on chromosome #1p selects for amplification of the N-myc proto-oncogene in human neuroblastoma cells.
    Grandinetti KB; Spengler BA; Biedler JL; Ross RA
    Oncogene; 2006 Feb; 25(5):706-12. PubMed ID: 16278682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.